Sarepta Therapeutics, Inc. SRPT Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $464.45M-42.0% | $801.28M+30.7% | $613.08M+20.1% | $510.6M+112% | $240.87M-78.2% | ||
| $188.74M+36.4% | $138.37M-41.8% | $237.92M-17.8% | $289.54M+2.7% | $281.9M+12.0% | ||
| $394.82M-0.9% | $398.23M+0.6% | $395.74M-24.9% | $527.3M-20.0% | $659.37M+9.5% | ||
| $174.87M-5.2% | $184.54M-7.1% | $198.6M+2.0% | $194.67M+7.5% | $181.16M-3.6% | ||
| $2.31B-9.0% | $2.54B-6.8% | $2.72B+2.5% | $2.66B+9.2% | $2.43B-20.9% | ||
| $336.24M-2.6% | $345.13M-3.8% | $358.94M-3.5% | $371.86M+3.1% | $360.59M+6.0% | ||
| $3.18B-5.1% | $3.35B-4.1% | $3.49B-5.1% | $3.68B+6.2% | $3.47B-12.6% | ||
| $70.38M-74.9% | $280.84M+199% | $94.02M-31.2% | $136.7M-12.4% | $156.11M-27.2% | ||
| $116.04M-73.8% | $443.4M-8.7% | $485.45M+22.8% | $395.43M+781% | $44.86M-65.6% | ||
| —— | —— | —— | —— | —— | ||
| $499.16M-54.4% | $1.1B+18.9% | $921.43M+0.2% | $919.95M+51.9% | $605.59M-17.2% | ||
| $1.67B-24.2% | $2.21B+1.6% | $2.17B-6.4% | $2.32B0.0% | $2.32B-4.6% | ||
| $11K0.0% | $11K0.0% | $11K+10.0% | $10K0.0% | $10K0.0% | ||
| -$4.55B+6.8% | -$4.88B-5.1% | -$4.64B-4.0% | -$4.46B+4.2% | -$4.66B-10.6% | ||
| $1.51B+32.0% | $1.14B-13.6% | $1.32B-2.7% | $1.36B+18.8% | $1.14B-25.2% | ||
| $3.18B-5.1% | $3.35B-4.1% | $3.49B-5.1% | $3.68B+6.2% | $3.47B-12.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can Sarepta Therapeutics, Inc. cover its short-term obligations?
- Its current ratio is 4.63 — current assets exceed current liabilities.
- Where does Sarepta Therapeutics, Inc.'s balance sheet data come from?
- Every line is extracted from Sarepta Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.